Skip to content
To the full analysis

Immunocore Holdings stock: balance sheet and debt

IMCR
$30.48Closing price of 12 Nov 2026MEQIRI Score 45 out of 100

Immunocore Holdings has a debt to equity ratio of 1.15.

Daily figure as of 13 Nov 2026

Debt / Equity
1.15
Interest coverage
−0.2x
Current ratio
4.04
Cash & equivalents
$864.15M
Total assets
$1.07B
Equity ratio
35.7%
Goodwill
not reported separately
Net debt
−$427.47M
More cash than debt

Total assets and equity ratio

How large the balance sheet of Immunocore Holdings plc is, how much of it is equity and how much is goodwill from acquisitions.

Equity ratio

Figures as a table
YearTotal assetsGoodwill and intangible assetsof which goodwillEquity ratioNet debt
2013$19.58M$257.77Knot split out15.3%−$16.32M
2014$60.87M$206.91Knot split out−3.5%−$50.84M
2015$273.53M$142.16Knot split out78.4%−$219.98M
2016$219.08M$371.84Knot split out79.9%−$176.51M
2017$198.04M$742.78Knot split out69.5%−$101.38M
2018$195.78M$318Knot split out28.9%−$105.51M
2019$245.94Mnot reported separatelynot reported separately8.0%−$19.29M
2020$197.19Mnot reported separatelynot reported separately28.1%−$102.31M
2021$407.28Mnot reported separatelynot reported separately56.8%−$234.9M
2022$526.76M$410not split out64.3%−$321.02M
2023$472.44Mnot reported separatelynot reported separately61.8%−$283.77M
2024$1.01Bnot reported separatelynot reported separately35.7%−$387.65M
2025$1.07Bnot reported separatelynot reported separately35.7%−$427.47M

The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt. In years without separate goodwill, the table shows the sum of goodwill and intangible assets, because the data do not list goodwill separately there.

Equity and debt

What the company owns and owes

  • Cash & equivalents
  • Equity
  • Debt
Figures as a table
YearCash & equivalentsEquityDebtDebt / Equity
2013$16.32M$3M$00
2014$50.84M−$2.1M$00
2015$219.98M$214.5M$00
2016$176.51M$174.98M$00
2017$118.54M$137.55M$17.17M0.12
2018$124.39M$56.58M$18.88M0.33
2019$97.99M$19.57M$78.7M4.02
2020$176.78M$55.35M$74.47M1.35
2021$321.06M$231.53M$86.16M0.37
2022$402.47M$338.9M$81.45M0.24
2023$350.27M$291.89M$66.5M0.23
2024$820.38M$360.72M$432.72M1.2
2025$864.15M$381.03M$436.69M1.15

Data status and sources

Score
Daily value of 13 Nov 2026, recalculated nightly
Price
Closing price of 12 Nov 2026
Latest annual report
Fiscal year 2025, period end 31 Dec 2025
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Weak, published since 7 Nov 2026 (in the score history since 28 Feb 2022)
  • Valuation signal Fairly valued since 7 Nov 2026
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy